These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 20430537)

  • 1. Optimal targeting of Hepatitis C virus treatment among injecting drug users to those not enrolled in methadone maintenance programs.
    Zeiler I; Langlands T; Murray JM; Ritter A
    Drug Alcohol Depend; 2010 Aug; 110(3):228-33. PubMed ID: 20430537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methadone maintenance and hepatitis C virus infection among injecting drug users.
    Crofts N; Nigro L; Oman K; Stevenson E; Sherman J
    Addiction; 1997 Aug; 92(8):999-1005. PubMed ID: 9376782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy.
    Palepu A; Tyndall MW; Joy R; Kerr T; Wood E; Press N; Hogg RS; Montaner JS
    Drug Alcohol Depend; 2006 Sep; 84(2):188-94. PubMed ID: 16542797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C seroprevalence amongst injecting drug users attending a methadone programme.
    Chetwynd J; Brunton C; Blank M; Plumridge E; Baldwin D
    N Z Med J; 1995 Sep; 108(1007):364-6. PubMed ID: 7566775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis C virus prevalence and outcomes among injecting drug users on opioid replacement therapy.
    Hallinan R; Byrne A; Amin J; Dore GJ
    J Gastroenterol Hepatol; 2005 Jul; 20(7):1082-6. PubMed ID: 15955218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What is the cost-effectiveness of hepatitis C treatment for injecting drug users on methadone maintenance in New Zealand?
    Sheerin IG; Green FT; Sellman JD
    Drug Alcohol Rev; 2004 Sep; 23(3):261-72. PubMed ID: 15370005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence rates and risk factors for hepatitis C among drug users not in treatment in Malaysia.
    Vicknasingam B; Narayanan S; Navaratnam V
    Drug Alcohol Rev; 2009 Jul; 28(4):447-54. PubMed ID: 19594801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis C virus infection and injection drug users: prevention, risk factors, and treatment.
    Backmund M; Reimer J; Meyer K; Gerlach JT; Zachoval R
    Clin Infect Dis; 2005 Apr; 40 Suppl 5():S330-5. PubMed ID: 15768343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors associated with methadone maintenance therapy use among a cohort of polysubstance using injection drug users in Vancouver.
    Kerr T; Marsh D; Li K; Montaner J; Wood E
    Drug Alcohol Depend; 2005 Dec; 80(3):329-35. PubMed ID: 15964714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users.
    Van Den Berg C; Smit C; Van Brussel G; Coutinho R; Prins M;
    Addiction; 2007 Sep; 102(9):1454-62. PubMed ID: 17697278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low risk for hepatitis C seroconversion in methadone maintenance treatment.
    Peles E; Schreiber S; Rados V; Adelson M
    J Addict Med; 2011 Sep; 5(3):214-20. PubMed ID: 21844836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of hepatitis C among drug users attending general practice in Ireland: baseline data from the Dublin area hepatitis C in general practice initiative.
    Cullen W; Stanley J; Langton D; Kelly Y; Bury G
    Eur J Gen Pract; 2007; 13(1):5-12. PubMed ID: 17366287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimating population attributable risk for hepatitis C seroconversion in injecting drug users in Australia: implications for prevention policy and planning.
    Wand H; Spiegelman D; Law M; Jalaludin B; Kaldor J; Maher L
    Addiction; 2009 Dec; 104(12):2049-56. PubMed ID: 19804463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High prevalence of HCV in a cohort of injectors on methadone substitution treatment.
    Lee KC; Lim WW; Lee SS
    J Clin Virol; 2008 Apr; 41(4):297-300. PubMed ID: 18191614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales.
    Sutton AJ; Gay NJ; Edmunds WJ; Hope VD; Gill ON; Hickman M
    BMC Infect Dis; 2006 Jun; 6():93. PubMed ID: 16762050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: challenges and opportunities.
    Litwin AH; Soloway I; Gourevitch MN
    Clin Infect Dis; 2005 Apr; 40 Suppl 5():S339-45. PubMed ID: 15768345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of, and risk factors for, hepatitis C virus infection among recent initiates to injecting in London and Glasgow: cross sectional analysis.
    Judd A; Hutchinson S; Wadd S; Hickman M; Taylor A; Jones S; Parry JV; Cameron S; Rhodes T; Ahmed S; Bird S; Fox R; Renton A; Stimson GV; Goldberg D
    J Viral Hepat; 2005 Nov; 12(6):655-62. PubMed ID: 16255768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frontloading: a risk factor for HIV and hepatitis C virus infection among injecting drug users in Berlin.
    Stark K; Müller R; Bienzle U; Guggenmoos-Holzmann I
    AIDS; 1996 Mar; 10(3):311-7. PubMed ID: 8882671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of former heroin addict patients with Hepatitis C virus antibodies in a methadone maintenance treatment (MMT) clinic in israel.
    Peles E; Rados V; Adelson M
    Subst Use Misuse; 2007; 42(9):1477-84. PubMed ID: 17886143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk behaviors and antibody hepatitis B and C prevalence among injecting drug users in south-western Sydney, Australia.
    Maher L; Chant K; Jalaludin B; Sargent P
    J Gastroenterol Hepatol; 2004 Oct; 19(10):1114-20. PubMed ID: 15377287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.